IKNA
vs
S&P 500
IKNA
S&P 500
Over the past 12 months, IKNA has underperformed S&P 500, delivering a return of -14% compared to the S&P 500's +14% growth.
Stocks Performance
IKNA vs S&P 500
Performance Gap
IKNA vs S&P 500
Performance By Year
IKNA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Ikena Oncology Inc
Glance View
Ikena Oncology, Inc. is a clinical stage biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing cancer therapies targeting signaling pathways that drive the formation and spread of cancer. Its oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain (TEAD), transcription factor in the Hippo signaling pathway. The company intends to pursue clinical development of IK-930 across a range of tumor types with known Hippo pathway mutations. Its oncology programs also include extracellular signal-related kinase 5 (ERK5) inhibitor / RAS Signaling Pathway inhibitor program, RAS Pathway discovery programs, Tumor Microenvironment Programs, IK-175, IK-412 and IK-007. The firm is developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway. The company also has early stage discovery programs in targeted oncology in the RAS pathway.